New York, United States
Helex is making significant strides in the biotechnology arena by addressing the high unmet needs of kidney disease treatment. With its slogan, "Genomic medicines for kidney diseases with high unmet need," Helex aims to revolutionize the therapeutic landscape for renal conditions.
Incorporated in 2021, the company's unique approach lies in its proprietary kidney tropic lipid nanoparticle delivery system, enhanced by the Epic-Cure(TM) 3D genome-based drug designer platform. This fusion enables the creation of innovative and precise therapies specifically targeting renal diseases. Their flagship asset is a mutation-agnostic therapy aimed at Autosomal Dominant Polycystic Kidney Disease, a condition that affects over 4 million individuals worldwide.
Based in the United States and also operating within the clean energy sector, Helex secured a $3.50M seed investment on 01 October 2025, with backing from investors such as SOSV, pi Ventures, and Bluehill Capital. The company’s strategy positions it as a promising candidate for future investment in the transformative biotech space.
